GO:1904707 positive regulation of vascular associated smooth muscle cell proliferation: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1904707 describes any process that activates or increases the frequency, rate or extent of vascular smooth muscle cell (VSMC) proliferation.
• VSMC proliferation is a hallmark of vascular remodeling in atherosclerosis, restenosis, hypertension, and pulmonary arterial hypertension.
• Key drivers include epigenetic regulators such as G9a and PRMT5, metabolic enzymes such as LDHA, and matricellular proteins.
• Endogenous brakes on VSMC proliferation include SIRT6, KCNMB1, and Sox9, which protect against senescence, phenotypic switching, and vascular aging.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to establish causality for candidate regulators of VSMC proliferation.
• GO:1904707 is a biological_process term, distinct from negative regulation (GO:1904708) and from generic cell proliferation terms.
Description
GO:1904707, positive regulation of vascular associated smooth muscle cell proliferation, is a Gene Ontology biological_process term that captures any signaling event or molecular mechanism that activates or increases the frequency, rate, or extent of vascular smooth muscle cell (VSMC) proliferation. VSMCs are the predominant cell type in the arterial media, and their ability to switch from a quiescent, contractile phenotype to a proliferative, synthetic phenotype is a central event in vascular remodeling. This phenotypic plasticity is essential for vessel repair after injury, but when dysregulated it drives neointimal hyperplasia, atherosclerosis, and pulmonary vascular remodeling. Researchers study GO:1904707 because it sits at the intersection of cardiovascular disease, epigenetics, metabolism, and inflammation. For example, the histone methyltransferase G9a drives VSMC proliferation and intimal hyperplasia in mice, while PRMT5-mediated arginine methylation stabilizes KLF4 to accelerate neointimal formation. Conversely, SIRT6 protects smooth muscle cells from senescence and reduces atherosclerosis, and reduced KCNMB1 expression promotes VSMC phenotypic switch and apoptosis. These findings establish that positive regulation of VSMC proliferation is not a single pathway but a convergence point for epigenetic, metabolic, and matricellular signals. Because GO:1904707 is defined by its directionality (positive regulation), it is experimentally distinguished from negative regulation of VSMC proliferation and from baseline proliferation assays. Functional annotation of this term typically requires perturbation experiments, such as CRISPR knockout or overexpression of candidate genes, combined with proliferation readouts like EdU incorporation, Ki-67 staining, or cell counting. This article synthesizes the QuickGO definition with verified PubMed literature to provide a research-grade overview of the term, its mechanisms, key genes, disease relevance, and experimental models.
positive regulation of vascular associated smooth muscle cell proliferation At A Glance
| GO ID | GO:1904707 |
|---|---|
| GO term | positive regulation of vascular associated smooth muscle cell proliferation |
| Ontology | biological_process |
| Synonym | activation of VSMC proliferation; upregulation of vascular smooth muscle cell proliferation; positive regulation of VSMC proliferation |
| Major function | Increases the frequency, rate, or extent of vascular smooth muscle cell proliferation during vascular remodeling, injury response, and disease |
| Directionality | Positive regulation (distinct from negative regulation of VSMC proliferation) |
| Cell type | Vascular associated smooth muscle cells (VSMCs) |
| Disease relevance | Atherosclerosis, restenosis, neointimal hyperplasia, pulmonary arterial hypertension, vascular aging |
| Experimental readouts | EdU/BrdU incorporation, Ki-67 staining, cell counting, proliferation markers |
What Is GO:1904707?
GO:1904707 is defined by QuickGO as any process that activates or increases the frequency, rate or extent of vascular smooth muscle cell proliferation. In practical terms, it is the positive-regulatory arm of VSMC proliferation biology: it includes the receptors, kinases, transcription factors, epigenetic modifiers, and metabolic enzymes whose activation leads to more VSMCs entering the cell cycle and dividing. It is a biological_process term, and its synonyms include activation of VSMC proliferation and upregulation of vascular smooth muscle cell proliferation.
Why Is positive regulation of vascular associated smooth muscle cell proliferation Important in Cell Biology?
GO:1904707 matters because VSMC proliferation is a final common pathway in many cardiovascular diseases. In atherosclerosis, VSMCs migrate from the media to the intima and proliferate, contributing to plaque stability and lesion progression. In restenosis after angioplasty or stenting, uncontrolled VSMC proliferation causes neointimal hyperplasia and vessel narrowing. In pulmonary arterial hypertension, lactate dehydrogenase A (LDHA)-mediated lactate generation promotes pulmonary vascular remodeling, a process dependent on VSMC proliferation. In vascular aging, Sox9 accelerates aging by regulating extracellular matrix composition and stiffness, which in turn influences VSMC behavior. Understanding the positive regulators of VSMC proliferation therefore provides mechanistic targets for therapeutic intervention in cardiovascular disease.
• Central driver of neointimal hyperplasia and restenosis after vascular injury.
• Contributes to atherosclerotic plaque formation and progression.
• Promotes pulmonary vascular remodeling in pulmonary arterial hypertension.
• Linked to vascular aging through extracellular matrix stiffness and Sox9 signaling.
• Regulated by epigenetic enzymes such as G9a and PRMT5, making it druggable.
• Counterbalanced by protective factors such as SIRT6 and KCNMB1.
• Requires precise experimental models to distinguish proliferation from migration or apoptosis.
• Serves as a functional annotation node for CRISPR screens and transcriptomic studies.
• Relevant to both systemic and pulmonary vascular diseases.
• Provides a testable hypothesis space for gene editing-based target validation.
What Happens During positive regulation of vascular associated smooth muscle cell proliferation?
Initiation: Mitogenic and Metabolic Signals
In simple terms: The process starts when signals tell VSMCs to divide.
Positive regulation of VSMC proliferation begins with extracellular and intracellular signals that push quiescent, contractile VSMCs toward a synthetic, proliferative phenotype. Metabolic reprogramming is one such signal: LDHA-mediated lactate generation promotes pulmonary vascular remodeling, indicating that glycolytic flux supports the proliferative program. Matricellular proteins in the extracellular matrix also provide pro-proliferative cues during atherosclerosis development. These initiating signals converge on cell-cycle entry and are required for the subsequent stages of proliferation.
Epigenetic and Transcriptional Control
In simple terms: Special proteins that package DNA decide which proliferation genes are turned on.
Epigenetic modifiers are central positive regulators of VSMC proliferation. The histone methyltransferase G9a drives VSMC proliferation and intimal hyperplasia in mice, demonstrating that histone methylation is causally linked to this process. Protein arginine methyltransferase 5 (PRMT5)-mediated arginine methylation stabilizes Kruppel-like factor 4 (KLF4) to accelerate neointimal formation, linking arginine methylation to transcriptional control of the proliferative response. These findings show that chromatin-modifying enzymes can act as master positive regulators of GO:1904707.
Phenotypic Switching and Contractile Marker Loss
In simple terms: VSMCs stop being contractile and become proliferative.
A hallmark of positive regulation of VSMC proliferation is phenotypic switching, in which contractile markers are downregulated and synthetic/proliferative markers are upregulated. Reduced expression of KCNMB1 leads to VSMC phenotypic switch and apoptosis, indicating that loss of this subunit disrupts the normal contractile state. Small nucleolar RNA host gene 18 (SNHG18) controls the VSMC contractile phenotype and neointimal hyperplasia, further supporting the idea that non-coding RNAs and their targets regulate the switch between contractile and proliferative states. This stage is often measured by loss of ACTA2, MYH11, and CNN1 and gain of proliferation markers.
Cell-Cycle Entry and DNA Synthesis
In simple terms: The cells actually copy their DNA and divide.
The defining output of GO:1904707 is increased cell-cycle entry and DNA synthesis. Experimentally, this is assessed by EdU or BrdU incorporation, Ki-67 staining, and direct cell counting. Positive regulators such as G9a and PRMT5 increase the fraction of VSMCs in S phase, whereas protective factors such as SIRT6 reduce senescence and atherosclerosis by limiting proliferative and inflammatory responses. This stage distinguishes positive regulation from mere activation of signaling, because it requires a measurable increase in proliferation frequency or rate.
Resolution and Pathological Consequences
In simple terms: If the process is not stopped, it causes vessel narrowing and disease.
In normal vascular repair, VSMC proliferation is transient and resolves. In disease, sustained positive regulation leads to neointimal hyperplasia, atherosclerosis, and pulmonary vascular remodeling. Sox9 accelerates vascular aging by regulating extracellular matrix composition and stiffness, which can perpetuate pro-proliferative and pro-fibrotic signals. SIRT6 protects smooth muscle cells from senescence and reduces atherosclerosis, illustrating an endogenous brake on this process. Thus, the balance between positive and negative regulation determines whether VSMC proliferation is adaptive or pathological.
Key Genes Involved in GO:1904707 positive regulation of vascular associated smooth muscle cell proliferation
The following genes and proteins have been experimentally linked to positive regulation of vascular associated smooth muscle cell proliferation in the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| G9a (EHMT2) | Histone methyltransferase that drives VSMC proliferation and intimal hyperplasia | Epigenetic target for restenosis; knockout reduces neointimal formation |
| PRMT5 | Arginine methyltransferase that stabilizes KLF4 and accelerates neointimal formation | Methylation-dependent regulator of VSMC proliferation |
| KLF4 | Transcription factor stabilized by PRMT5 to promote neointimal formation | Downstream effector of PRMT5 in VSMC proliferation |
| LDHA | Lactate dehydrogenase A; lactate generation promotes pulmonary vascular remodeling | Metabolic regulator of VSMC proliferation in pulmonary hypertension |
| SIRT6 | Sirtuin that protects smooth muscle cells from senescence and reduces atherosclerosis | Endogenous brake on VSMC proliferation and inflammation |
| KCNMB1 | Calcium-activated potassium channel subunit; reduced expression causes phenotypic switch and apoptosis | Regulator of VSMC contractile phenotype |
| SNHG18 | Small nucleolar RNA host gene 18; controls contractile phenotype and neointimal hyperplasia | Non-coding RNA regulator of VSMC phenotype |
| Sox9 | Transcription factor that accelerates vascular aging via ECM composition and stiffness | Links ECM remodeling to VSMC behavior in aging |
| ACTA2 | Smooth muscle alpha-actin; contractile marker lost during phenotypic switching | Readout of contractile vs. synthetic VSMC state |
| MYH11 | Smooth muscle myosin heavy chain; contractile marker | Marker of differentiated VSMCs |
| CNN1 | Calponin 1; contractile marker | Marker of contractile VSMC phenotype |
| PCNA | Proliferation marker; indicates DNA synthesis | Readout of VSMC proliferation |
| Ki-67 | Proliferation marker expressed in cycling cells | Quantifies proliferating VSMCs |
| Matricellular proteins (e.g., thrombospondins, tenascins) | ECM proteins that modulate VSMC proliferation in atherosclerosis | Link ECM remodeling to VSMC proliferation |
| ECM components (collagen, elastin) | Structural matrix whose composition and stiffness change with age and disease | Mechanotransduction inputs to VSMC proliferation |
| Inflammatory cytokines (e.g., IL-6, TNF-alpha) | Pro-inflammatory signals that can promote VSMC proliferation | Connect inflammation to VSMC proliferation |
How Is positive regulation of vascular associated smooth muscle cell proliferation Regulated?
Positive regulation of VSMC proliferation is controlled at multiple levels. Epigenetically, G9a-mediated histone methylation and PRMT5-mediated arginine methylation promote proliferative gene expression. Metabolically, LDHA-mediated lactate generation supports pulmonary vascular remodeling, linking glycolysis to proliferation. Endogenous negative regulators such as SIRT6 and KCNMB1 counteract these pro-proliferative signals. Extracellular matrix composition and stiffness, regulated in part by Sox9, provide mechanical and biochemical inputs that modulate VSMC behavior during aging. Matricellular proteins in the atherosclerotic microenvironment further tune proliferative responses. Together, these layers form a regulatory network in which the balance between positive and negative inputs determines the extent of VSMC proliferation.
positive regulation of vascular associated smooth muscle cell proliferation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| G9a (EHMT2) | Neointimal hyperplasia and restenosis | VSMC-specific knockout or pharmacological inhibition in mouse injury models |
| PRMT5 | Neointimal formation and atherosclerosis | Knockout or methyltransferase-dead point mutant in VSMCs |
| LDHA | Pulmonary arterial hypertension and vascular remodeling | LDHA knockout or overexpression in pulmonary VSMCs |
| SIRT6 | Atherosclerosis and VSMC senescence | SIRT6 knockout or overexpression in ApoE-/- mice |
| KCNMB1 | VSMC phenotypic switch and apoptosis | KCNMB1 knockdown or knockout in cultured VSMCs |
Atherosclerosis and Vascular Aging
Atherosclerosis involves VSMC migration and proliferation that contribute to plaque formation and stability. SIRT6 protects smooth muscle cells from senescence and reduces atherosclerosis, indicating that loss of this protection enhances pro-proliferative and inflammatory programs. Sox9 accelerates vascular aging by regulating extracellular matrix composition and stiffness, which can promote a pro-proliferative microenvironment. Matricellular proteins in the atherosclerotic plaque further modulate VSMC behavior. These findings position GO:1904707 as a central node in atherosclerosis and vascular aging.
Neointimal Hyperplasia and Restenosis
After vascular injury, VSMCs proliferate and migrate to form a neointima, leading to restenosis. G9a drives VSMC proliferation and intimal hyperplasia in mice, and PRMT5-mediated KLF4 stabilization accelerates neointimal formation. SNHG18 controls the VSMC contractile phenotype and neointimal hyperplasia, linking non-coding RNA regulation to this disease process. These studies establish positive regulation of VSMC proliferation as a causal mechanism in restenosis.
Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is characterized by pulmonary vascular remodeling, in which VSMC proliferation is a key component. LDHA-mediated lactate generation promotes pulmonary vascular remodeling, suggesting that metabolic reprogramming supports VSMC proliferation in this disease. This connects GO:1904707 to metabolic and hypoxic signaling in the pulmonary vasculature.
VSMC Phenotypic Switch and Apoptosis
Reduced expression of KCNMB1 leads to VSMC phenotypic switch and apoptosis, indicating that loss of contractile regulators can disrupt the balance between proliferation and cell death. This highlights that positive regulation of VSMC proliferation is often studied alongside phenotypic switching and apoptosis, and that disease outcomes depend on the net balance of these processes.
From positive regulation of vascular associated smooth muscle cell proliferation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is G9a required for VSMC proliferation in vivo? | VSMC-specific G9a knockout mouse with carotid injury |
| Does PRMT5 methylation of KLF4 drive neointimal formation? | PRMT5 knockout or methylation-dead knock-in in VSMCs |
| Does LDHA-mediated lactate production promote pulmonary vascular remodeling? | LDHA knockout or overexpression in pulmonary VSMCs |
| Does SIRT6 protect against atherosclerosis by limiting VSMC proliferation? | SIRT6 overexpression or knockout in ApoE-/- mice |
| Does KCNMB1 loss cause phenotypic switch and apoptosis? | KCNMB1 knockdown or knockout in cultured VSMCs |
| Does SNHG18 control contractile phenotype and neointimal hyperplasia? | SNHG18 knockout or overexpression in VSMCs |
How to Study the positive regulation of vascular associated smooth muscle cell proliferation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| EdU/BrdU incorporation | DNA synthesis and S-phase entry | Quantify VSMC proliferation in vitro and in vivo |
| Ki-67 staining | Cells in active cell cycle | Assess proliferation in tissue sections |
| RNA-seq | Transcriptome changes | Identify proliferative and contractile gene signatures |
| ChIP-seq | Histone modification and transcription factor binding | Map G9a-dependent epigenetic programs |
| Lactate assay | Glycolytic flux and LDHA activity | Link metabolism to pulmonary vascular remodeling |
| Immunoblotting | Protein expression and stability | Assess KLF4 stabilization by PRMT5 |
| Carotid injury model | Neointimal hyperplasia | Test causality of candidate genes in vivo |
| Immunofluorescence | Contractile and proliferation markers | Evaluate phenotypic switching |
Proliferation Assays
EdU and BrdU incorporation measure DNA synthesis, while Ki-67 staining and direct cell counting quantify proliferating VSMCs. These assays are the primary readouts for GO:1904707 and are used to determine whether a candidate gene positively regulates VSMC proliferation. They are often combined with contractile marker staining (ACTA2, MYH11, CNN1) to assess phenotypic switching.
Transcriptomic and Epigenomic Profiling
RNA-seq can identify gene expression changes associated with VSMC phenotypic switching and proliferation. Chromatin immunoprecipitation followed by sequencing (ChIP-seq) for histone marks such as H3K9me2 can reveal G9a-dependent epigenetic programs. These methods help define the transcriptional and epigenetic networks downstream of positive regulators.
Metabolic and Proteomic Analyses
Metabolic assays measuring lactate production and glycolytic flux can link LDHA activity to VSMC proliferation. Proteomic approaches can identify methylation-dependent protein stability changes, such as PRMT5-mediated KLF4 stabilization. These methods connect metabolism and post-translational modifications to GO:1904707.
In Vivo Vascular Injury Models
Carotid artery ligation or balloon injury models in mice are used to assess neointimal hyperplasia, a direct consequence of VSMC proliferation. These models allow researchers to test whether genetic perturbations alter intimal thickening and VSMC proliferation in a physiological context.
How CRISPR Can Be Used to Study GO:1904707 positive regulation of vascular associated smooth muscle cell proliferation
Knockout
CRISPR knockout of candidate positive regulators such as G9a or PRMT5 in VSMCs can determine whether they are required for proliferation and neointimal formation. Knockout models are essential for establishing loss-of-function causality in GO:1904707. For example, VSMC-specific G9a knockout reduces intimal hyperplasia in mice.
Point Mutation
Point mutations can dissect specific enzymatic activities or post-translational modification sites. For instance, a methyltransferase-dead mutant of PRMT5 or a methylation-site mutant of KLF4 can test whether arginine methylation is required for neointimal formation. Such models provide mechanistic resolution beyond simple knockout.
Knock-in
Knock-in of tagged or reporter alleles allows visualization and quantification of endogenous proteins in VSMCs. Tagged knock-in of KLF4 or SIRT6 can be used to track protein stability and localization during proliferation. Knock-in of disease-associated variants can also model human vascular disease.
Overexpression
Overexpression of positive regulators such as LDHA or G9a can drive VSMC proliferation and vascular remodeling, while overexpression of protective factors such as SIRT6 can suppress it. Overexpression models are useful for gain-of-function studies and for testing therapeutic hypotheses.
How EDITGENE Supports positive regulation of vascular associated smooth muscle cell proliferation Research
Researchers studying positive regulation of vascular associated smooth muscle cell proliferation-related genes often need to determine whether a candidate gene is causally involved in VSMC proliferation or simply correlated with it. Establishing causality requires precise genetic perturbation, ideally in relevant vascular cell types and in vivo models. EDITGENE provides end-to-end CRISPR services to generate knockout, point-mutation, knock-in, and overexpression cell models, as well as CRISPR library screening and bioinformatics support, enabling rigorous functional annotation of GO:1904707.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of vascular associated smooth muscle cell proliferation research.
Frequently Asked Questions About positive regulation of vascular associated smooth muscle cell proliferation
What is GO:1904707?
GO:1904707 is the Gene Ontology biological_process term for positive regulation of vascular associated smooth muscle cell proliferation, defined as any process that activates or increases the frequency, rate or extent of VSMC proliferation.
What genes are involved in positive regulation of vascular smooth muscle cell proliferation?
Key genes include G9a, PRMT5, KLF4, LDHA, SIRT6, KCNMB1, SNHG18, and Sox9, all of which have been experimentally linked to VSMC proliferation or phenotypic switching.
How is VSMC proliferation measured in the lab?
Common methods include EdU/BrdU incorporation, Ki-67 staining, cell counting, and proliferation marker immunoblotting.
What diseases are associated with VSMC proliferation?
VSMC proliferation is associated with atherosclerosis, restenosis, neointimal hyperplasia, pulmonary arterial hypertension, and vascular aging.
What is the difference between positive and negative regulation of VSMC proliferation?
Positive regulation (GO:1904707) increases VSMC proliferation, while negative regulation decreases it. Both are biological_process terms that describe opposite directions of regulation.
Which epigenetic enzymes regulate VSMC proliferation?
G9a and PRMT5 are histone and arginine methyltransferases, respectively, that promote VSMC proliferation and neointimal formation.
How does SIRT6 affect VSMC proliferation?
SIRT6 protects smooth muscle cells from senescence and reduces atherosclerosis, acting as an endogenous brake on pro-proliferative and inflammatory programs.
What role does LDHA play in vascular remodeling?
LDHA-mediated lactate generation promotes pulmonary vascular remodeling, linking glycolytic metabolism to VSMC proliferation in pulmonary hypertension.
Can CRISPR be used to study VSMC proliferation?
Yes. CRISPR knockout, point-mutation, knock-in, and overexpression models are widely used to establish causality for candidate regulators of VSMC proliferation.
What is the role of KLF4 in neointimal formation?
PRMT5-mediated arginine methylation stabilizes KLF4, which accelerates neointimal formation, linking KLF4 to positive regulation of VSMC proliferation.
Conclusion
GO:1904707, positive regulation of vascular associated smooth muscle cell proliferation, is a biologically and clinically important Gene Ontology term that captures the signaling, epigenetic, and metabolic processes driving VSMC proliferation. Its dysregulation contributes to atherosclerosis, restenosis, pulmonary arterial hypertension, and vascular aging. Understanding its mechanisms requires integrating proliferation assays, transcriptomics, epigenomics, and in vivo vascular injury models. CRISPR-based approaches are indispensable for establishing causality in this process, and EDITGENE provides comprehensive knockout, point-mutation, knock-in, overexpression, and library screening services to accelerate research on GO:1904707.
References
- 1. Faleeva M et al.. 2024. Sox9 Accelerates Vascular Aging by Regulating Extracellular Matrix Composition and Stiffness.. Circ Res 134(3):307-324 PMID: 38179698
- 2. Grootaert MOJ et al.. 2021. SIRT6 Protects Smooth Muscle Cells From Senescence and Reduces Atherosclerosis.. Circ Res 128(4):474-491 PMID: 33353368
- 3. Wu D et al.. 2024. Lactate dehydrogenase A (LDHA)-mediated lactate generation promotes pulmonary vascular remodeling in pulmonary hypertension.. J Transl Med 22(1):738 PMID: 39103838
- 4. Liu H et al.. 2025. Reduced expression of KCNMB1 leads to vascular smooth muscle cell phenotypic switch and apoptosis.. Biochem Pharmacol 241:117151 PMID: 40653026
- 5. Niu K et al.. 2024. Small nucleolar RNA host gene 18 controls vascular smooth muscle cell contractile phenotype and neointimal hyperplasia.. Cardiovasc Res 120(7):796-810 PMID: 38498586
- 6. Pervaiz N et al.. 2023. Matricellular proteins in atherosclerosis development.. Matrix Biol 120:1-23 PMID: 37086928
- 7. Liu ST et al.. 2026. Histone methyltransferase G9a drives vascular smooth muscle cell proliferation and intimal hyperplasia in mice.. Acta Pharmacol Sin 47(6):1561-1577 PMID: 41663737
- 8. Liu H et al.. 2023. Protein arginine methyltransferase 5-mediated arginine methylation stabilizes Kruppel-like factor 4 to accelerate neointimal formation.. Cardiovasc Res 119(11):2142-2156 PMID: 37201513
